超过半数被认为对乙酰氨基酚过量所致急性肝衰竭的患者血浆中检测不到对乙酰氨基酚
该回顾性分析纳入434例因对乙酰氨基酚毒性被判定为急性肝损伤或急性肝衰竭的受试者,发现52%的患者血浆中对乙酰氨基酚检测不到。检测不到与检测到对乙酰氨基酚的患者在人口学特征、酒精使用、转氨酶中位数及N-乙酰半胱氨酸使用上无显著差异。作者结论认为临床医生不应因对乙酰氨基酚检测不到而排除对乙酰氨基酚毒性或停用N-乙酰半胱氨酸。
要点
- 52%的因对乙酰氨基酚毒性被判定为急性肝损伤或急性肝衰竭的患者血浆中对乙酰氨基酚检测不到。
- 检测到与检测不到对乙酰氨基酚的两组患者在人口学特征、酒精使用、转氨酶中位数及N-乙酰半胱氨酸使用上无显著差异。
- 作者认为临床医生不应因对乙酰氨基酚检测不到而排除对乙酰氨基酚毒性或停用N-乙酰半胱氨酸。
核心结论
- 超过半数因对乙酰氨基酚毒性被判定为急性肝损伤或急性肝衰竭的患者血浆中对乙酰氨基酚检测不到。
- 临床医生不应因对乙酰氨基酚检测不到而排除对乙酰氨基酚毒性,也不应因此对疑似对乙酰氨基酚毒性的急性肝损伤或急性肝衰竭患者停用N-乙酰半胱氨酸。
研究设计与样本
- 回顾性分析急性肝衰竭研究组434例受试者数据,纳入2010年1月1日至2014年12月31日期间因对乙酰氨基酚毒性符合急性肝衰竭(首发症状26周内出现凝血障碍和肝性脑病,无既往肝病)或急性肝损伤(严重肝损伤伴凝血障碍但无脑病)标准的患者。
- 收集人口学、生化特征、报告的对乙酰氨基酚使用、N-乙酰半胱氨酸治疗、肝移植和结局数据。
- 采用描述性统计评估人口学、临床特征和结局,采用Wilcoxon秩和检验分析入院时对乙酰氨基酚检测到与未检测到患者间连续变量的差异。
- 主要目的是确定血浆中对乙酰氨基酚可检测到的患者比例。
主要发现
- 227例患者(52%)血清样本中对乙酰氨基酚检测不到。
- 检测到与检测不到对乙酰氨基酚的两组患者在人口学特征、酒精使用、丙氨酸天冬氨酸氨基转移酶中位数或N-乙酰半胱氨酸使用上无显著差异(检测到组94.7% vs 检测不到组95.9%使用N-乙酰半胱氨酸;P=.63)。
- 检测到对乙酰氨基酚组报告摄入剂量中位数为29,500 mg(四分位距15,000 mg-50,007 mg),检测不到原药组为14,950 mg(四分位距3960 mg-25,000 mg),差异有统计学意义(P=.003)。
- 单变量分析中,检测到对乙酰氨基酚组无肝移植生存比例(72.3%)低于检测不到组(86.3%)(P=.0006),但多变量分析中无统计学显著性(P=.12)。
- 自杀性过量患者中对乙酰氨基酚可检测到的比例(43%)高于意外性过量患者(29.3%;P=.01)。
临床怎么用
- 作者认为临床医生不应因对乙酰氨基酚检测不到而排除对乙酰氨基酚毒性。
- 作者认为对疑似对乙酰氨基酚毒性的急性肝损伤或急性肝衰竭患者,不应因对乙酰氨基酚检测不到而停用N-乙酰半胱氨酸。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Evaluation of patients with acute liver injury (ALI) or acute liver failure (ALF) often includes measurement of plasma levels of acetaminophen, to determine exposure and/or toxicity. However, once liver injury has developed, acetaminophen might be undetectable in plasma. We investigated the association between level of acetaminophen measured and outcomes of patients designated as having ALF or ALI due to acetaminophen toxicity. METHODS: We performed a retrospective analysis of data from 434 subjects in the Acute Liver Failure Study Group who met criteria for ALF (coagulopathy and hepatic encephalopathy within 26 weeks of the first symptoms, without pre-existing liver disease) or ALI (severe liver injury with coagulopathy but no encephalopathy) due to acetaminophen toxicity from January 1, 2010 through December 31, 2014. We collected data on patient demographics, biochemical features, reported acetaminophen use, N-acetylcysteine therapy, liver transplant, and outcomes. Descriptive statistics were used to assess patient demographics, clinical characteristics, and outcomes whereas differences in continuous variables between patients with vs without acetaminophen detection on admission were analyzed using the Wilcoxon rank-sum test. The primary aim was to determine the proportion of patients with detectable plasma levels of acetaminophen. RESULTS: Acetaminophen was undetectable in serum samples from 227 patients (52%). There were no significant differences between groups of patients with detectable vs undetectable levels in demographic features, alcohol use, median levels of alanine aspartate, or use of N-acetylcysteine (given to 94.7% of patients with detectable acetaminophen vs 95.9% of those with undetectable acetaminophen; P=.63). We observed a significant difference in median dose taken between patients with detectable (29,500 mg; interquartile range, 15,000 mg-50,007 mg) vs no detectable parent compound (14,950 mg; interquartile range, 3960 mg-25,000) (P=.003). A lower proportion of patients with detectable plasma levels of acetaminophen (72.3%) survived without a liver transplant than of patients with undetectable levels (86.3%) in univariate analysis (P=.0006), although this was not significant in multivariable analysis (P=.12). Although most patients had unintentional overdoses, a higher proportion of patients with suicidal overdoses (43%) had detectable levels of acetaminophen than patients with accidental overdoses (29.3%; P=.01). CONCLUSION: More than half of patients who present at the hospital with acetaminophen-induced ALI or ALF have undetectable levels of acetaminophen. Clinicians should not exclude acetaminophen toxicity because of undetectable levels or withhold N-acetylcysteine for patients with ALI or ALF when acetaminophen toxicity is suspected.
引用
- Leventhal TM, Gottfried M, Olson JC, et al. Acetaminophen is Undetectable in Plasma From More Than Half of Patients Believed to Have Acute Liver Failure Due to Overdose. Clin Gastroenterol Hepatol. 2019. PMID: 30731196. doi:10.1016/j.cgh.2019.01.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。